Second Biosimilar Insulin OK'd; Diabetes Risk After COVID; Omnipod DASH Recall

(MedPage Today) -- The FDA approved the second interchangeable biosimilar insulin product, Eli Lilly's insulin glargine-aglr (Rezvoglar), for pediatric and adult patients with diabetes, the agency announced.
Patients with diabetes and chronic...